6533b870fe1ef96bd12cf24a

RESEARCH PRODUCT

5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study

Luciano RausaSergio PalmeriVittorio Gebbia

subject

0301 basic medicineOncologymyalgiamedicine.medical_specialtymedicine.medical_treatmentInjections Subcutaneous030106 microbiologyAlpha interferonInterferon alpha-2Gastroenterology03 medical and health sciences0302 clinical medicineBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansPharmacology (medical)PharmacologyChemotherapyPerformance statusbusiness.industryCarcinomaInterferon-alphamedicine.diseaseRecombinant ProteinsInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisToxicityFluorouracilmedicine.symptombusinessColorectal Neoplasmsmedicine.drug

description

A dose optimization study was carried out with the aim of identifying the maximally tolerated dose of recombinant alpha interferon-2a (raIFN-2a) in combination with 5-fluorouracil (5FU). 5FU was given at the dose of 750 mg/m2 over a 4-hour infusion on day 1- - greater than 5 followed by 750 mg/m2 weekly i.v. bolus. Recombinant aIFN-2a was started at 3 x 10(6) IU subcutaneously three times/week. 12 patients with advanced colorectal carcinoma were included in the study. 10 patients had previously received chemotherapy for advanced disease. Severe fatigue, most likely attributable to rIFN, was the dose-limiting toxicity. The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU. At this dose level all patients required dose reduction due to fatigue, fever, myalgia and severe reduction of performance status.

yearjournalcountryeditionlanguage
1990-10-01
http://www.scopus.com/inward/record.url?eid=2-s2.0-0025241955&partnerID=MN8TOARS